Epigenetic Dysregulation Validation in Parkinson's Disease

📖 Wiki Page

experiment678 wordssynced 2026-04-02

Experiment Design: PD-EPI-001

Study Overview

This multi-phase experiment aims to validate the Epigenetic Dysregulation Hypothesis in Parkinson's Disease by examining DNA methylation patterns, histone modifications, and non-coding RNA expression in patient-derived models and post-mortem brain tissue.

Rationale

The epigenetic dysregulation hypothesis proposes that cumulative epigenetic alterations drive PD pathogenesis. This experiment tests three key predictions:

SNCA epigenetic regulation — DNA hypomethylation at SNCA intron 1 promoter increases α-synuclein expression

Cellular vulnerability — Epigenetic changes in dopaminergic neurons create loss of cellular identity

Therapeutic modulation — Epigenetic interventions (HDAC inhibitors, DNMT inhibitors) reduce neurodegeneration

Study Design

Phase 1: Epigenetic Profiling (Months 1-6)

Objective: Characterize baseline epigenetic alterations in PD patient samples

Cohort:

50 PD patients (Hoehn & Yahr 1-3)
50 age-matched healthy controls
20 early-stage drug-naïve PD patients (for epigenetic changes vs. treatment effects)

Samples:

Peripheral blood mononuclear cells (PBMCs) for blood-based biomarkers
Post-mortem substantia nigra tissue (10 PD, 10 controls) from brain bank
iPSC-derived dopaminergic neurons (20 PD patients with LRRK2/GBA mutations, 20 controls)

Endpoints:

Genome-wide DNA methylation (EPIC array)
ATAC-seq for chromatin accessibility
Small RNA-seq for miRNA/lncRNA profiling
H3K9me3, H3K27ac ChIP-seq in iPSC neurons

...

Experiment Design: PD-EPI-001

Study Overview

Rationale

The epigenetic dysregulation hypothesis proposes that cumulative epigenetic alterations drive PD pathogenesis. This experiment tests three key predictions:

SNCA epigenetic regulation — DNA hypomethylation at SNCA intron 1 promoter increases α-synuclein expression

Cellular vulnerability — Epigenetic changes in dopaminergic neurons create loss of cellular identity

Therapeutic modulation — Epigenetic interventions (HDAC inhibitors, DNMT inhibitors) reduce neurodegeneration

Study Design

Phase 1: Epigenetic Profiling (Months 1-6)

Objective: Characterize baseline epigenetic alterations in PD patient samples

Cohort:

50 PD patients (Hoehn & Yahr 1-3)
50 age-matched healthy controls
20 early-stage drug-naïve PD patients (for epigenetic changes vs. treatment effects)

Samples:

Peripheral blood mononuclear cells (PBMCs) for blood-based biomarkers
Post-mortem substantia nigra tissue (10 PD, 10 controls) from brain bank
iPSC-derived dopaminergic neurons (20 PD patients with LRRK2/GBA mutations, 20 controls)

Endpoints:

Genome-wide DNA methylation (EPIC array)
ATAC-seq for chromatin accessibility
Small RNA-seq for miRNA/lncRNA profiling
H3K9me3, H3K27ac ChIP-seq in iPSC neurons

Phase 2: Mechanistic Validation (Months 7-12)

Objective: Validate causal relationship between epigenetic changes and disease mechanisms

Models:

iPSC-derived dopaminergic neurons from PD patients and controls
CRISPR epigenetic editing (dCas9-DNMT3A, dCas9-TET1) to modulate SNCA promoter methylation
In vivo: AAV-mediated epigenetic editing in mouse substantia nigra

Interventions:

HDAC inhibitor treatment (sodium butyrate, valproic acid)
DNMT inhibitor treatment (5-azacytidine)
BET inhibitor treatment (JQ1)

Endpoints:

SNCA mRNA and protein expression
Mitochondrial function ( Seahorse assay)
Alpha-synuclein aggregation (Thioflavin S, seed amplification assay)
Neuronal survival (TUNEL, caspase-3 activation)

Phase 3: Biomarker Validation (Months 13-18)

Objective: Validate peripheral epigenetic biomarkers for diagnosis and progression

Cohort:

200 PD patients (longitudinal, 2-year follow-up)
100 at-risk individuals (LRRK2/GBA carriers)
50 prodromal PD (RBD positive)

Endpoints:

Blood DNA methylation signatures (prospective validation)
Correlation with clinical progression (MDS-UPDRS)
Comparison with existing biomarkers (α-synuclein in CSF)

Statistical Analysis

Power Calculation

Phase 1: 80% power to detect effect size d=0.5 at α=0.05
Phase 2: 80% power for in vitro endpoints with n=20 per group
Phase 3: 80% power for biomarker correlation with r=0.3

Primary Endpoints

DNA methylation at SNCA promoter (bisulfite pyrosequencing)

α-Synuclein expression in neurons (Western blot)

Neuronal survival (cell viability assay)

Secondary Endpoints

Mitochondrial respiration (OCR)

Inflammatory markers (IL-1β, IL-6 in culture supernatant)

Blood biomarker sensitivity/specificity (ROC analysis)

Expected Results

If Hypothesis Supported

Significant SNCA promoter hypomethylation in PD neurons
Reversal of epigenetic changes reduces α-synuclein aggregation
Blood-based epigenetic biomarkers show >75% sensitivity for PD diagnosis

If Hypothesis Not Supported

No significant epigenetic changes at SNCA locus
Epigenetic interventions show no neuroprotective effect
Biomarker validation fails to reach significance

Risks and Mitigations

| Risk | Mitigation |
|------|------------|
| iPSC differentiation variability | Use standardized protocol, quality controls |
| Epigenetic editing off-target effects | Validate with whole-genome sequencing |
| Blood-brain discrepancy | Include brain tissue validation |
| Drug delivery to substantia nigra | Use convection-enhanced delivery |

Budget Estimate

| Phase | Estimated Cost |
|-------|---------------|
| Phase 1 | $800,000 |
| Phase 2 | $600,000 |
| Phase 3 | $400,000 |
| Total | $1,800,000 |

Timeline

Month 1-6: Phase 1 (Epigenetic Profiling)
Month 7-12: Phase 2 (Mechanistic Validation)
Month 13-18: Phase 3 (Biomarker Validation)
Month 19-24: Data analysis and publication

Cross-Links

[Hypothesis: [Epigenetic Dysregulation Hypothesis in Parkinson's Disease](/hypotheses/epigenetic-dysregulation-parkinsons)](/diseases/parkinsons-disease)
[Related Mechanisms:](/content/mechanisms)
[DNA Damage Repair Deficiency](/hypotheses/dna-damage-repair-deficiency-parkinsons)
[Alpha-synuclein aggregation](/mechanisms/synucleinopathies)
[Neuroinflammation](/hypotheses/nlrp3-inflammasome-parkinsons)
[Therapeutic Targets:](/genes/ar)
[HDAC inhibitors](/mechanisms/sirt1-activators-parkinsons)
[Epigenetic drugs](/mechanisms/epigenetic-dysregulation-pathway)

References

[Kundel et al., Protocol for deriving dopaminergic neurons from iPSCs (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)

[Song et al., ATAC-seq for epigenetic analysis in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)

[Wang et al., Single-cell ATAC-seq of Parkinson's disease brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Chen et al., Epigenetic drug screening in iPSC models of PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Pathway Diagram

The following diagram shows key molecular relationships for Epigenetic Dysregulation Validation in Parkinson's Disease based on knowledge graph edges:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic Dysregulation Validation in Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →